ClinicalTrials.gg
Active, not recruitingNCT06517732ANIMA-RUpdated Apr 16, 2026

Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS) in Routine Clinical Practice in the Russian Federation

An observational study in Hidradenitis Suppurativa, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 19 sites in Russia. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
107
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Hidradenitis Suppurativa by Novartis — 9 open to participants now, 14 under way, 3 of them phase 3. Hidradenitis Suppurativa · Novartis.

Enrollment
6th of 10
107 · median 125
Started
2024
with 1 other
Observational
10 of 21
6 open now
Primary completion
2026-12
later than 1 of 13 live
Registered
9th of 21
by date

Among the 21 studies in Hidradenitis Suppurativa by Novartis, this one is the 6th largest by enrollment of the 10 observational ones that give a count, is one of 2 that started in 2024, is one of 10 observational ones, reaches primary completion later than 1 of the 13 other live ones, and was the 9th registered.

Hidradenitis Suppurativa

286 studies on the registry are indexed under Hidradenitis Suppurativa; 89 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

9 of the 21 studies in Hidradenitis Suppurativa by Novartis are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 63 Hidradenitis Suppurativa studies recruiting now, 35 (56%) set no upper age limit and 17 (27%) stop at 75 or younger; 13 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Hidradenitis Suppurativa by Novartis, or all of them as a file.
02

Study summary

ANIMA-R is an observational, prospective, non-interventional, multicenter study to assess real-world effectiveness of secukinumab in the treatment of Hidradenitis Suppurativa (HS).

Read the detailed description

The index date will be the date of secukinumab initiation. During the study, data will be collected from patients receiving routine secukinumab treatment, which is representative of the actual patient population.

The attending physician will decide whether to prescribe secukinumab based on the approved instructions for medical use in a routine clinical setting, regardless of the patient's participation in a non-interventional study.

03

Conditions studied

  • Hidradenitis Suppurativa

Keywords

  • Hidradenitis Suppurativa
  • HS
  • real-world data
  • secukinumab
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with moderate to severe Hidradenitis Suppurativa commencing treatment with secukinumab

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who provide written form (ICF) to participate in the study.
  2. Male and female.
  3. ≥ 18 years old.
  4. Diagnosis of moderate or severe HS (Hurley stage and IHS4).
  5. Patient who initiated treatment with secukinumab no longer than 4 weeks prior to written ICF.
  6. Decision for secukinumab prescription was made by the attending physician according to the approved national label during routine clinical practice, regardless of study participation.

Exclusion criteria

Exclusion Criteria:

  1. Any medical or psychological condition that may prevent the study participation, based on practitioners' decision-making.
  2. Participation in an ongoing clinical trial.
  3. Known or suspected severe for secukinumab, formulation , or injection device components (i.e., latex).
  4. infection exacerbation, including active tuberculosis.
  5. Patients with active inflammatory bowel disease (IBD).
  6. Age \<18 years.
  7. Pregnancy and breastfeeding.
  8. Patients who received any vaccine within 4 weeks prior to secukinumab initiation.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
107 participants (actual)
Patient registry
No

Groups and cohorts

  • Secukinumab

    Patients prescribed with secukinumab in the treatment of Hidradenitis Suppurativa

    Other: Secukinumab

Interventions

  • OtherSecukinumab

    This is an observational study. There is no treatment allocation. The decision to initiate secukinumab will be based solely on clinical judgement.

06

What researchers measure

Primary outcomes

  1. Proportion of patients achieving 55% reduction in IHS4 (IHS4-55)

    The International Hidradenitis Suppurativa Severity Scoring System (IHS4) allows for a dynamic assessment of the disease severity both in clinical studies and in real-world clinical setting. The IHS4 is determined by counting nodules, abscesses, and draining tunnels (fistulae/sinuses). IHS4 (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + \[number of draining tunnels (fistulae/sinuses) multiplied by 4\]. A score of 3 or lower indicates a mild stage of hidradenitis suppurativa, a score of 4-10 indicates a moderate stage, and a score of 11 or higher indicates a severe stage of the disease. The IHS4 severity scoring system assumes that the presence of a draining tunnel (fistula/sinus) is sufficient to classify a case as at least moderate.

    Time frame: 12 months

Secondary outcomes

  1. Proportion of patients receiving HS-specific concomitant treatments in combination with secukinumab

    Proportion of patients receiving Hidradenitis Suppurativa (HS)-specific concomitant treatments in combination with secukinumab

    Time frame: 12 months

  2. Time of initiation of concomitant medication

    Time of initiation of concomitant medication (before or after the initiation of secukinumab).

    Time frame: 12 months

  3. Duration of treatment with concomitant medication

    Duration of treatment with concomitant medication of secukinumab

    Time frame: 12 months

  4. Number, type, and outcome of surgical interventions

    Number, type, and outcome of surgical interventions (minor and major surgical excision; inpatient, outpatient, or self-treatment at home)

    Time frame: 12 months

  5. Timepoint of and reason for surgical intervention

    Timepoint of and reason for surgical intervention.

    Time frame: 12 months

  6. Duration of discontinuation/pause of secukinumab treatment before surgery

    Duration of discontinuation/pause of secukinumab treatment before surgery

    Time frame: 12 months

  7. Duration of discontinuation/pause of secukinumab treatment after surgery

    Duration of discontinuation/pause of secukinumab treatment after surgery

    Time frame: 12 months

  8. Surgery outcome

    Surgery outcome by type of wound healing, pain relief and discontinuation or continuation of secukinumab.

    Time frame: 12 months

  9. Outcome of surgery and adverse events stratified by secukinumab management

    Outcome of surgery (healing, pain relief) and adverse events (i.e., infections) stratified by secukinumab management (continuation or discontinuation).

    Time frame: 12 months

  10. Predictors of treatment response

    Listing of predictors of treatment response

    Time frame: 12 months

  11. Proportion of patients achieving 75% reduction in IHS4 (IHS4-75) and 100% reduction in IHS4 (IHS4-100)

    The International Hidradenitis Suppurativa Severity Scoring System (IHS4) allows for a dynamic assessment of the disease severity both in clinical studies and in real-world clinical setting. The IHS4 is determined by counting nodules, abscesses, and draining tunnels (fistulae/sinuses). IHS4 (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + \[number of draining tunnels (fistulae/sinuses) multiplied by 4\]. A score of 3 or lower indicates a mild stage of hidradenitis suppurativa, a score of 4-10 indicates a moderate stage, and a score of 11 or higher indicates a severe stage of the disease. The IHS4 severity scoring system assumes that the presence of a draining tunnel (fistula/sinus) is sufficient to classify a case as at least moderate.

    Time frame: Month 6, month 12

  12. Lesion spread

    Lesion spread (defined as total abscess and inflammatory nodule count (AN) or draining fistula in a body region not seen at baseline) assessed by number, type, and localization of HS lesions

    Time frame: Baseline, month 6, month 12

  13. Mean change of nodule count

    Mean reduction of nodule count

    Time frame: Month 6, month 12

07

Study locations

19 sites
  • Novartis Investigative Site
    Izhevsk, 426039, Russia
  • Novartis Investigative Site
    Kaliningrad, 236016, Russia
  • Novartis Investigative Site
    Kaliningrad, 236029, Russia
  • Novartis Investigative Site
    Kazan', 420012, Russia
  • Novartis Investigative Site
    Kemerovo, 650025, Russia
  • Novartis Investigative Site
    Krasnodar, 350020, Russia
  • Novartis Investigative Site
    Moscow, 107076, Russia
  • Novartis Investigative Site
    Moscow, 119881, Russia
  • Novartis Investigative Site
    Moscow, 123182, Russia
  • Novartis Investigative Site
    Moscow, 129110, Russia
  • Novartis Investigative Site
    Nizhny Novgorod, 603950, Russia
  • Novartis Investigative Site
    Penza, 440052, Russia
  • Novartis Investigative Site
    Saint Petersburg, 197022, Russia
  • Novartis Investigative Site
    Samara, 443079, Russia
  • Novartis Investigative Site
    Saratov, 410028, Russia
  • Novartis Investigative Site
    Stavropol, 355020, Russia
  • Novartis Investigative Site
    Tula, 300053, Russia
  • Novartis Investigative Site
    Ufa, 450010, Russia
  • Novartis Investigative Site
    Yakutsk, 677000, Russia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Dec 2026, 29 months after the start.

Of 46 observational studies under Hidradenitis Suppurativa, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 25. This study's planned 29 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2024
First posted
Jul 24, 2024
StartActual
Jul 26, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06517732
Responsible party
Sponsor
First posted
Jul 24, 2024
Start date
Jul 26, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 16, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion